Literature DB >> 19018760

Association of visceral fat accumulation and plasma adiponectin with rectal dysplastic aberrant crypt foci in a clinical population.

Hirokazu Takahashi1, Tetsuji Takayama, Kyoko Yoneda, Hiroki Endo, Hiroshi Iida, Michiko Sugiyama, Koji Fujita, Masato Yoneda, Masahiko Inamori, Yasunobu Abe, Satoru Saito, Koichiro Wada, Hitoshi Nakagama, Atsushi Nakajima.   

Abstract

The association between obesity and the risk of colorectal cancer (CRC) cannot be easily evaluated because CRC itself is associated with a gradual loss of bodyweight. Aberrant crypt foci (ACF) can be classified as dysplastic ACF or non-dysplastic ACF by magnifying colonoscopy, and dysplastic ACF are thought to be a biomarker of CRC. Ninety-four participants who underwent colonoscopy at Yokohama City University Hospital, Japan, were enrolled in the current study. We detected 557 ACF, including 67 dysplastic ACF (12.0%). Univariate regression analysis was conducted to determine correlations between the number of dysplastic ACF and various potential risk factors, including patient age, waist circumference, body mass index, visceral fat area (VFA), and plasma adiponectin level. The results of multiple regression analysis revealed that the number of dysplastic ACF correlated with age (correlation coefficient r=0.212, P=0.0383) and plasma adiponectin level (r=-0.201, P=0.0371), even after adjustments for sex, waist circumference, body mass index, and VFA. Our univariate correlation analysis data showed a significant correlation with the number of dysplastic ACF with VFA (r=0.238, P=0.0209), no correlation with subcutaneous fat area, and an inverse correlation with the plasma level of adiponectin (r=-0.258, P=0.0118). Thus, our results suggest that aging and visceral fat accumulation could correlate moderately with colorectal carcinogenesis. The novelty of our study lies in the finding that visceral fat accumulation and a low plasma adiponectin level may promote colorectal carcinogenesis; therefore, these obesity-related parameters may serve as novel targets for CRC prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018760     DOI: 10.1111/j.1349-7006.2008.00994.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Adipose tissue-organotypic culture system as a promising model for studying adipose tissue biology and regeneration.

Authors:  Shuji Toda; Kazuyoshi Uchihashi; Shigehisa Aoki; Emiko Sonoda; Fumio Yamasaki; Meihua Piao; Akifumi Ootani; Nobuhisa Yonemitsu; Hajime Sugihara
Journal:  Organogenesis       Date:  2009-04       Impact factor: 2.500

Review 2.  Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.

Authors:  Małgorzata Muc-Wierzgoń; Ewa Nowakowska-Zajdel; Sylwia Dzięgielewska-Gęsiak; Teresa Kokot; Katarzyna Klakla; Edyta Fatyga; Elżbieta Grochowska-Niedworok; Dariusz Waniczek; Janusz Wierzgoń
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Relationship of human rectal aberrant crypt foci and formation of colorectal polyp: One-year following up after polypectomy.

Authors:  Hirokazu Takahashi; Eiji Yamada; Hidenori Ohkubo; Eiji Sakai; Takuma Higurashi; Takashi Uchiyama; Kunihiro Hosono; Hiroki Endo; Atsushi Nakajima
Journal:  World J Gastrointest Endosc       Date:  2012-12-16

4.  Waist circumference predicts increased complications in rectal cancer surgery.

Authors:  Courtney J Balentine; Celia N Robinson; Christy R Marshall; Jonathan Wilks; William Buitrago; Kujtim Haderxhanaj; Shubhada Sansgiry; Nancy J Petersen; Vivek Bansal; Daniel Albo; David H Berger
Journal:  J Gastrointest Surg       Date:  2010-09-11       Impact factor: 3.452

5.  Obesity and colorectal cancer.

Authors:  Irena Gribovskaja-Rupp; Lauren Kosinski; Kirk A Ludwig
Journal:  Clin Colon Rectal Surg       Date:  2011-12

Review 6.  Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer.

Authors:  Prashant Kant; Mark A Hull
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.